<?xml version="1.0" encoding="UTF-8"?>
<p id="p0035">In the past, physicians could rely on clinical signs and symptoms to diagnose an ailing patient with influenza. However, due to the level of shared signs, symptoms, differentiating between influenza and COVID-19 will usually require diagnostic testing [
 <xref rid="bib4" ref-type="bibr">4</xref>,
 <xref rid="bib6" ref-type="bibr">6</xref>]. Obtaining the correct diagnosis for a patient presenting with a viral illness is paramount for determining the best course of treatment, particularly since the treatment for influenza has not been shown to be effective in treating COVID-19 patients. Treatments for influenza are anti-virals which include oseltamivir phosphate, zanamivir, peramivir, and baloxavir marboxil [
 <xref rid="bib1" ref-type="bibr">1</xref>]. On the contrary, COVID-19 currently does not have FDA approved anti-viral medication. There is however an emergency use authorization for dexamethasone and the anti-viral remdesivir [
 <xref rid="bib7" ref-type="bibr">7</xref>].
</p>
